NDA 208794 · Tersera
Xermelo
Telotristat Etiprate · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Feb 28, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
5 Phase 3, 0 recruiting
FAERS reports
5,748
2,025 serious, 411 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 6, 2026.
Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. ( 1 )
Mechanism: Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate limiting step in serotonin biosynthesis. The in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl. Serotonin plays a role in mediating secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Through inhibition of tryptophan hydroxylase, telotristat and telotristat ethyl reduce the production of peripheral serotonin, and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- XERMELO · TELOTRISTAT ETIPRATE EQ 250MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Telotristat Etiprate" as an intervention, any sponsor and status, largest first.
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)Pivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT01677910 · 135 participants · Start Jan 8, 2013 · Primary completion Mar 21, 2016
Drug: Telotristat etiprate; Placebo-matching telotristat etiprate · For: Carcinoid Syndrome
Sites: Mobile, Alabama; Palo Alto, California; San Francisco, California · 75 sites in all
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsPivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT02026063 · 124 participants · Start Jan 14, 2014 · Primary completion Sep 12, 2018
Drug: Telotristat etiprate · For: Carcinoid Syndrome
Sites: Mobile, Alabama; Stanford, California; Iowa City, Iowa · 43 sites in all
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04810091 · 79 participants · Start May 18, 2021 · Primary completion Aug 31, 2025
Drug: Placebo Administration; Telotristat Ethyl · For: Locally Advanced Neuroendocrine Neoplasm; Metastatic Neuroendocrine Neoplasm
Sites: Houston, Texas
- Telotristat Etiprate for Carcinoid Syndrome TherapyPivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT02063659 · 76 participants · Start Mar 11, 2014 · Primary completion Mar 29, 2016
Drug: Telotristat etiprate; Placebo · For: Carcinoid Syndrome
Sites: Stanford, California; Orlando, Florida; Iowa City, Iowa · 50 sites in all
Lexicon PharmaceuticalsIndustry
NCT01456052 · 59 participants · Start Jan 30, 2012 · Primary completion Sep 3, 2013
Drug: Telotristat Etiprate; Placebo · For: Ulcerative Colitis
Sites: Little Rock, Arkansas; Anaheim, California; Santa Monica, California · 24 sites in all
TerSera Therapeutics LLCIndustry
NCT03790111 · 53 participants · Start Mar 13, 2019 · Primary completion Jan 13, 2022
Drug: telotristat ethyl · For: Biliary Tract Cancer (BTC)
Sites: Gilbert, Arizona; Fullerton, California; Gainesville, Florida · 14 sites in all
Lexicon PharmaceuticalsIndustry
NCT02155205 · 48 participants · Start May 2014 · Primary completion Aug 2014
Drug: Telotristat etiprate; Placebo and 1 more · For: QT Interval
Sites: Evansville, Indiana
Lexicon PharmaceuticalsIndustry
NCT03302845 · 32 participants · Start Sep 21, 2017 · Primary completion Oct 23, 2017
Drug: Omeprazole 40 MG; Famotidine 40 mg and 1 more · For: Drug-drug Interaction
Sites: Dallas, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea841
- nausea630
- constipation606
- off label use521
- abdominal pain519
- fatigue419
- flatulence398
- flushing353
- death340
- headache328
- drug ineffective322
- malaise255
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2017 | 1,264 |
| 2018 | 1,722 |
| 2019 | 1,188 |
| 2020 | 812 |
| 2021 | 377 |
| 2022 | 111 |
| 2023 | 96 |
| 2024 | 65 |
| 2025 | 57 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xermelo (Telotristat Etiprate)
2024 spending
$24.2M
Beneficiaries
419
2,551 claims
Per beneficiary
$57,710
$113.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $12,401,503 |
| 2023 | $18,340,851 |
| 2024 | $24,180,481 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert MO, Kaltsas G, Hörsch D, et al. · Clin Ther 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel M, Hörsch D, Caplin M, et al. · J Clin Endocrinol Metab 2015 · Clinical Trial, Multicenter Study
- Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH, O'Dorisio T, Phan A, et al. · Endocr Relat Cancer 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.
Gelhorn HL, Kulke MH, O'Dorisio T, et al. · Clin Ther 2016 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Tersera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.